欧洲联盟批准AstraZeneca的Fassenra为EGPA, 扩大其罕见疾病组合。 European Union approves AstraZeneca's Fasenra for EGPA, expanding its rare disease portfolio.

欧盟已批准阿斯瑞卡公司的Fasenra用于治疗多炎带来的菌粒体病 (EGPA). The European Union has approved AstraZeneca's Fasenra for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). 这一决定是该公司的一个重要里程碑,加强了其稀有疾病定向疗法的组合。 This decision is a significant milestone for the company, enhancing its portfolio in targeted therapies for rare diseases.